Metastatic Pancreatic Cancer: Are We Making Progress in Treatment?
Development of systemic treatment for advanced pancreatic cancer (APC) has been challenging. After fluorouracil, gemcitabine (GEM) became the treatment of choice based on its benefit of symptom relief. Many cytotoxic agents have been combined with GEM in search of regimens with improved survival ben...
Main Authors: | Joanne Chiu, Thomas Yau |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2012-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2012/898931 |
Similar Items
-
Are we making progress in diagnosing and preventing gastrointestinal cancers?
by: Jelle Haringsma, et al.
Published: (2010-07-01) -
Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer
by: FNU Asad ur Rahman, et al.
Published: (2017-07-01) -
Are we making progress in preventing Barrett's-related esophageal cancer?
by: Julian A. Abrams
Published: (2009-03-01) -
Transcriptome analysis of the procession from chronic pancreatitis to pancreatic cancer and metastatic pancreatic cancer
by: Jihao Tu, et al.
Published: (2021-02-01) -
Personalization of Chemotherapy for Metastatic Pancreatic Cancer
by: Yuriko (Ito) Sasahara, et al.
Published: (2014-07-01)